Sector News

Sequana announces results from study of direct sodium removal

November 19, 2022
Life sciences

Sequana, a company focusing on liver disease, heart failure and cancer has announced positive top-line results from SAHARA – the phase 2a study using its first-generation direct sodium removal (DSR) product, DSR 1.0.

Data from ten evaluable diuretic-resistant heart failure patients, with persistent congestion, who also completed a 16-week follow-up period after intensive DSR therapy, confirmed previously reported interim data demonstrating long-lasting clinical benefits.

At baseline, the patients with persistent congestion due to heart failure were on high dose loop diuretics and had high disease severity. All ten individuals safely, effectively and rapidly eliminated persistent congestion and achieved euvolemia within one week of commencing intensive DSR therapy, resulting in a mean weight loss of 7kg.

Furthermore, during the intensive DSR period, the diuretic response of the kidney was near-normalised, with excretion of sodium increasing more than 160% compared to the baseline. In addition, there was a considerable improvement in cardio-renal health.

Dr Jeffrey Testani, associate professor at Yale University and heart failure scientific advisor to Sequana Medical, explained: “Congestion is a key driver of heart failure and remains the leading cause of morbidity and hospitalisation in this large and growing patient population. Diuretic-resistance is widespread and the usual therapeutic approach is just adding more diuretics, further worsening the underlying issues.

He added: “There are no therapies that seek to correct the cardio-renal pathophysiology causing the diuretic-resistance.”

Dr Oliver Gödje, chief medical officer at Sequana Medical, added: “These results are very positive and reinforce our view that DSR is a potential disease-modifying heart failure therapy. We are excited to have the first patient dosed with DSR 2.0 and we are confident that this second-generation product will deliver important therapeutic and safety benefits.”

To evaluate the safety, tolerability and efficacy of the company’s second-generation DSR product – DSR 2.0 – a phase 1 study has been initiated in Canada with up to ten patients on peritoneal dialysis receiving a single treatment. Meanwhile, a further phase 1 study is due to take place in Mexico, followed by a randomised phase 1/2a study in the US during 2023.

By John Pinching


comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.